|Exchange:||NASDAQ national market|
|Stock:||Delcath Systems, Inc.|
|Industry:||Drug Manufacturers - Specialty & Generic|
|Delcath Systems, Inc., is a Delaware corporation incorporated in August 1988.The Company is a pharmaceutical and medical device company focused on oncology, initially cancers in the liver. Since its inception, it has directed its research efforts towards the development and clinical study of the Delcath chemosaturation system. The Company currently operates in one business segment, which is the development and commercialization of the Delcath chemosaturation system. The Delcath chemosaturation system allows the administration of concentrated regional chemotherapy by isolating the circulatory system of the targeted organ. Once the organ is isolated, the Delcath chemosaturation system delivers high doses of chemotherapeutic agents directly to the liver, while limiting systemic exposure and the related side effects by filtering the blood prior to returning it to the patient. The Delcath chemosaturation system involves a series of three catheter insertions, each of which is placed percutaneously through standard interventional radiology techniques. The procedure is minimally invasive and repeatable allowing for multiple courses of treatment with chemotherapeutic drugs and the potential for concomitant cancer therapies. The Company assembles, sterilizes and packages the Delcath chemosaturation system at its facility in Queensbury, New York and has established its European headquarters and distribution facility in Galway, Ireland. It utilizes contract manufacturers to manufacture some components of the Delcath chemosaturation system. The Delcath chemosaturation system competes with all forms of liver cancer treatments. The Delcath chemosaturation system is subject to extensive and rigorous government regulation by foreign regulatory agencies and the FDA.|
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.